Avalo Therapeutics, Inc.
AVTX
$9.88
$0.515.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.59% | 151.10% | -11.37% | 76.02% | -46.25% |
| Total Depreciation and Amortization | 145.70% | 69.81% | 6.96% | -4.00% | 5.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -19.47% |
| Total Other Non-Cash Items | -147.39% | -199.96% | -215.64% | -392.70% | 7.13% |
| Change in Net Operating Assets | 143.82% | 74.97% | 49.05% | 57.86% | -37.46% |
| Cash from Operations | -47.78% | -94.97% | -59.90% | -15.46% | -66.32% |
| Capital Expenditure | -- | -- | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -100.00% | -100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -20,004.49% | -100.00% | 367.67% | 367.67% | 306.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -154.07% |
| Issuance of Common Stock | -50.92% | -53.13% | 299.84% | 149.37% | 592.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 76.83% | 68.54% | -- | -- | -- |
| Cash from Financing | -43.42% | -43.93% | 602.22% | 330.45% | 723.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -158.59% | -84.02% | 2,303.24% | 1,144.86% | 1,829.65% |